Cargando…

Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)

BACKGROUND: A combination of clinical and routine laboratory data with biomarkers reflecting different pathophysiological pathways may help to refine risk stratification in heart failure (HF). A novel calculator (BCN Bio-HF calculator) incorporating N-terminal pro B-type natriuretic peptide (NT-proB...

Descripción completa

Detalles Bibliográficos
Autores principales: Lupón, Josep, de Antonio, Marta, Vila, Joan, Peñafiel, Judith, Galán, Amparo, Zamora, Elisabet, Urrutia, Agustín, Bayes-Genis, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893213/
https://www.ncbi.nlm.nih.gov/pubmed/24454874
http://dx.doi.org/10.1371/journal.pone.0085466
_version_ 1782299643384692736
author Lupón, Josep
de Antonio, Marta
Vila, Joan
Peñafiel, Judith
Galán, Amparo
Zamora, Elisabet
Urrutia, Agustín
Bayes-Genis, Antoni
author_facet Lupón, Josep
de Antonio, Marta
Vila, Joan
Peñafiel, Judith
Galán, Amparo
Zamora, Elisabet
Urrutia, Agustín
Bayes-Genis, Antoni
author_sort Lupón, Josep
collection PubMed
description BACKGROUND: A combination of clinical and routine laboratory data with biomarkers reflecting different pathophysiological pathways may help to refine risk stratification in heart failure (HF). A novel calculator (BCN Bio-HF calculator) incorporating N-terminal pro B-type natriuretic peptide (NT-proBNP, a marker of myocardial stretch), high-sensitivity cardiac troponin T (hs-cTnT, a marker of myocyte injury), and high-sensitivity soluble ST2 (ST2), (reflective of myocardial fibrosis and remodeling) was developed. METHODS: Model performance was evaluated using discrimination, calibration, and reclassification tools for 1-, 2-, and 3-year mortality. Ten-fold cross-validation with 1000 bootstrapping was used. RESULTS: The BCN Bio-HF calculator was derived from 864 consecutive outpatients (72% men) with mean age 68.2±12 years (73%/27% New York Heart Association (NYHA) class I-II/III-IV, LVEF 36%, ischemic etiology 52.2%) and followed for a median of 3.4 years (305 deaths). After an initial evaluation of 23 variables, eight independent models were developed. The variables included in these models were age, sex, NYHA functional class, left ventricular ejection fraction, serum sodium, estimated glomerular filtration rate, hemoglobin, loop diuretic dose, β-blocker, Angiotensin converting enzyme inhibitor/Angiotensin-2 receptor blocker and statin treatments, and hs-cTnT, ST2, and NT-proBNP levels. The calculator may run with the availability of none, one, two, or the three biomarkers. The calculated risk of death was significantly changed by additive biomarker data. The average C-statistic in cross-validation analysis was 0.79. CONCLUSIONS: A new HF risk-calculator that incorporates available biomarkers reflecting different pathophysiological pathways better allowed individual prediction of death at 1, 2, and 3 years.
format Online
Article
Text
id pubmed-3893213
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38932132014-01-21 Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator) Lupón, Josep de Antonio, Marta Vila, Joan Peñafiel, Judith Galán, Amparo Zamora, Elisabet Urrutia, Agustín Bayes-Genis, Antoni PLoS One Research Article BACKGROUND: A combination of clinical and routine laboratory data with biomarkers reflecting different pathophysiological pathways may help to refine risk stratification in heart failure (HF). A novel calculator (BCN Bio-HF calculator) incorporating N-terminal pro B-type natriuretic peptide (NT-proBNP, a marker of myocardial stretch), high-sensitivity cardiac troponin T (hs-cTnT, a marker of myocyte injury), and high-sensitivity soluble ST2 (ST2), (reflective of myocardial fibrosis and remodeling) was developed. METHODS: Model performance was evaluated using discrimination, calibration, and reclassification tools for 1-, 2-, and 3-year mortality. Ten-fold cross-validation with 1000 bootstrapping was used. RESULTS: The BCN Bio-HF calculator was derived from 864 consecutive outpatients (72% men) with mean age 68.2±12 years (73%/27% New York Heart Association (NYHA) class I-II/III-IV, LVEF 36%, ischemic etiology 52.2%) and followed for a median of 3.4 years (305 deaths). After an initial evaluation of 23 variables, eight independent models were developed. The variables included in these models were age, sex, NYHA functional class, left ventricular ejection fraction, serum sodium, estimated glomerular filtration rate, hemoglobin, loop diuretic dose, β-blocker, Angiotensin converting enzyme inhibitor/Angiotensin-2 receptor blocker and statin treatments, and hs-cTnT, ST2, and NT-proBNP levels. The calculator may run with the availability of none, one, two, or the three biomarkers. The calculated risk of death was significantly changed by additive biomarker data. The average C-statistic in cross-validation analysis was 0.79. CONCLUSIONS: A new HF risk-calculator that incorporates available biomarkers reflecting different pathophysiological pathways better allowed individual prediction of death at 1, 2, and 3 years. Public Library of Science 2014-01-15 /pmc/articles/PMC3893213/ /pubmed/24454874 http://dx.doi.org/10.1371/journal.pone.0085466 Text en © 2014 Lupón et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lupón, Josep
de Antonio, Marta
Vila, Joan
Peñafiel, Judith
Galán, Amparo
Zamora, Elisabet
Urrutia, Agustín
Bayes-Genis, Antoni
Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
title Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
title_full Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
title_fullStr Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
title_full_unstemmed Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
title_short Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)
title_sort development of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (bcn bio-hf calculator)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893213/
https://www.ncbi.nlm.nih.gov/pubmed/24454874
http://dx.doi.org/10.1371/journal.pone.0085466
work_keys_str_mv AT luponjosep developmentofanovelheartfailurerisktoolthebarcelonabioheartfailureriskcalculatorbcnbiohfcalculator
AT deantoniomarta developmentofanovelheartfailurerisktoolthebarcelonabioheartfailureriskcalculatorbcnbiohfcalculator
AT vilajoan developmentofanovelheartfailurerisktoolthebarcelonabioheartfailureriskcalculatorbcnbiohfcalculator
AT penafieljudith developmentofanovelheartfailurerisktoolthebarcelonabioheartfailureriskcalculatorbcnbiohfcalculator
AT galanamparo developmentofanovelheartfailurerisktoolthebarcelonabioheartfailureriskcalculatorbcnbiohfcalculator
AT zamoraelisabet developmentofanovelheartfailurerisktoolthebarcelonabioheartfailureriskcalculatorbcnbiohfcalculator
AT urrutiaagustin developmentofanovelheartfailurerisktoolthebarcelonabioheartfailureriskcalculatorbcnbiohfcalculator
AT bayesgenisantoni developmentofanovelheartfailurerisktoolthebarcelonabioheartfailureriskcalculatorbcnbiohfcalculator